Core Insights - Allergan Aesthetics, a subsidiary of AbbVie, is showcasing its leadership in the aesthetic industry by presenting 17 abstracts at the 2025 American Society of Dermatologic Surgery (ASDS) Annual Meeting, including three in the "Top Ten" session [1][2] - The presentations will cover Phase 3 clinical study results for trenibotulinumtoxinE, a first-in-class botulinum neurotoxin, and a Phase 4 study on BOTOX® Cosmetic, focusing on patient satisfaction and natural outcomes [1][3] - The company emphasizes its commitment to evidence-based innovation and improving patient care through its diverse product portfolio [2] Presentation Highlights - Key presentations include the efficacy and safety of trenibotulinumtoxinE for treating glabellar lines, and patient-reported satisfaction following BOTOX® Cosmetic treatment for upper facial lines [4][5] - An expert panel will discuss insights from the "Hyaluronic Acid Injectable Fillers Report," focusing on current usage and satisfaction data for hyaluronic acid fillers [4] - A symposium will address the latest indications for BOTOX® Cosmetic, including treatment for moderate to severe platysma bands [4] Educational Initiatives - Allergan Aesthetics will host educational programs aimed at understanding patient needs and enhancing clinical practices [3] - Presentations will also cover the benefits of long-term BOTOX® Cosmetic use and survey results on aesthetic concerns following medical weight loss [3][4] Company Overview - Allergan Aesthetics develops and markets a wide range of aesthetic products, including facial injectables and body contouring solutions, with a focus on innovation and customer service [30] - AbbVie aims to address serious health issues through innovative medicines, with a significant presence in the aesthetics market [31]

Core Insights - Allergan Aesthetics is expanding the rollout of SKINVIVE by JUVÉDERM to 35 additional markets, bringing the total to 57 globally in 2025, highlighting the company's commitment to enhancing skin quality worldwide [1][5][9] - The global skin quality market is valued at $5.2 billion, with a notable shift in consumer behavior towards health-focused aesthetic solutions [2][6] Product and Market Expansion - SKINVIVE is described as the longest-lasting hydrating injectable on the market, providing deep hydration and smoothness with a single treatment [5][6] - The AA Signature™ approach, which includes SKINVIVE, aims to address diverse patient needs and improve skin quality, emphasizing a holistic treatment strategy [3][4] Consumer Insights - Research indicates that 94% of people desire to improve their facial skin quality, with deep hydration being a priority across all age groups [6][15] - Consumers are increasingly gravitating towards aesthetic treatments that yield natural-looking results, reflecting a desire for consistency and realistic outcomes rather than dramatic changes [6][15] Industry Events and Education - The Aesthetic Anti-Aging Medicine World Congress (AMWC) in Dubai will feature discussions on the AA Signature™ approach and its integration into aesthetic practices [4][7] - A dedicated panel of renowned experts will explore the complexities of skin quality and its emotional connections, furthering the educational efforts of Allergan Aesthetics [7]

Market Overview - The global Cellulite Treatment Market was valued at USD 2.30 billion in 2024 and is projected to reach USD 5.19 billion by 2032, expanding at a CAGR of 10.47% from 2025 to 2032 [1][7] - The U.S. market alone was worth USD 711.91 million in 2024 and is expected to grow at a CAGR of 10.54% [1][3] Growth Drivers - The market growth is driven by a shift in consumer preference towards non-invasive and minimally invasive procedures, along with continuous innovation in FDA-approved devices [3] - Societal focus on body shape and contour, influenced by media and lifestyle trends, is increasing the demand for quick, safe, and cost-effective cellulite reduction treatments [3] Market Segmentation By Treatment Procedure - Non-invasive procedures led the market in 2024, accounting for 62.52% of total revenue, and are projected to grow at the highest CAGR of 11.09% from 2023 to 2030 [8] - Popular non-invasive treatments include radiofrequency, ultrasound, acoustic wave, and laser therapy, with products like Emtone®, Venus Legacy®, and Velashape® driving market confidence [8] By Type of Cellulite - In 2024, soft cellulite accounted for the largest share at 47.18%, while hard cellulite registered the highest growth rate with a CAGR of 12.57% [9] By End-User - Specialty dermatology clinics captured the highest market share at 54.90% in 2024, attributed to patient confidence in licensed professionals and advanced technologies [10] - Ambulatory surgical centers (ASCs) are projected to be the most opportunistic segment due to rising demand for cost-effective outpatient procedures [10] Regional Analysis - North America accounted for 38.50% of the global market in 2024, supported by established healthcare infrastructure and high-income populations [12] - Europe, particularly Germany, France, Italy, and the UK, is also a significant market due to a mature aesthetic culture and access to advanced dermatology [12] - Asia-Pacific is anticipated to be the fastest-growing region with a CAGR of 11.26%, driven by increasing disposable income and medical tourism [13]

VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments. The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-b ...

Core Insights - Allergan Aesthetics, a subsidiary of AbbVie, has announced the 2025 class of entrepreneurs participating in The Confidence Project, an initiative aimed at empowering women entrepreneurs and closing the Confidence Gap [1][4]. Group 1: The Confidence Project Overview - The Confidence Project is led by BOTOX® Cosmetic and focuses on accelerating business growth for selected entrepreneurs from various industries and backgrounds [3]. - Participants will engage in a Virtual Community Summit that emphasizes business development, camaraderie, and financial coaching [3]. - Following the summit, entrepreneurs will enter an intensive "Boostcamp" powered by Hello Alice, providing practical tools, mentorship, and education to help scale their businesses [3][6]. Group 2: Grant and Selection Process - After the Boostcamp, select entrepreneurs will participate in a Pitch Lab to present their business ideas to a grant selection committee [4]. - A total of 20 entrepreneurs will be awarded a $20,000 grant each from BOTOX® Cosmetic to support their business goals [4][6]. - The selection panel includes executives from Allergan Aesthetics and established entrepreneurs in the aesthetics industry [4]. Group 3: Community and Impact - The initiative aims to foster a supportive community for women entrepreneurs, highlighting the importance of collaboration in building successful businesses [5]. - The announcement of the 20 grant recipients is scheduled for October 2025 [5].